Objective: To assess the attitude of husbands toward the thalassemic carrier screening test and to explore the causes of non-participation of having a blood test.
Study Design: Descriptive study.
Material And Method: During 2007-2008, 100 husbands of pregnant women with screening-positive test for thalassemia who refused to have blood test were enrolled by voluntariness. They would fill out a structured questionnaire designed for the present study which was divided into 3 parts; (1) participant's personal characteristics (2) their attitudes toward thalassemic carrier screening test with the score ranging from 1-5, and (3) reasons for their refusal of having a blood test.
Results: The husbands had a favorable attitude toward testing for thalassemia, with overall mean score and standard deviation of 3.57 and 0.38. Commonly expressed reasons against testing were the self-belief of having a non-affected child and the inconvenience of coming to the hospital.
Conclusion: Husbands had a favorable attitude toward test for thalassemia.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- * 60 thalassemia patients were divided into three groups based on their chelation treatments: oral deferiprone daily, subcutaneous deferoxamine four times weekly, and a combination of both therapies.
- * Results show that the combination therapy was the most effective in reducing iron levels and improving urinary iron excretion, while patients on deferoxamine had the least hepatic iron deposition, though still above normal levels.
One-step amplification refractory mutation system-PCR/high-resolution melting curve assay for carrier detection of red blood cell membranopathy caused by common SPTB mutations.
Int J Lab Hematol
April 2024
Pediatrics Hematology-Oncology, Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Article Synopsis
- Hereditary pyropoikilocytosis (HPP) is a serious blood condition common in Thailand, caused by specific gene mutations.
- Scientists created a new test to detect three common mutations in a single step, making it easier to check for carriers in healthy people.
- Their test worked well, identifying a small number of carriers among blood donors and teens, and it could help prevent babies from being born with HPP.
Concomitant Presence of Hb Agrinio and - -Med Deletion in a Greek Male Patient with Hemoglobinopathy H: More Severe Phenotype and Literature Review.
Hematol Rep
August 2023
First Department of Internal Medicine, General Hospital of Larissa, 41221 Larissa, Greece.
Hemoglobin (Hb) Agrinio is a rare non-deletional a-globin mutation observed almost exclusively in Greek, Spanish or other Mediterranean families. The clinical manifestations of a carrier of a single Hb Agrinio mutation (single heterozygosity) depend on the concomitant presence or absence of other mutations or variants in the beta, alpha or other modifying genes. We present a Greek patient harboring a Hb Agrinio variant plus the - -Med alpha deletional allele, having an infrequent severe form of alpha thalassemia, in contrast to the typical alpha thalassemic patient and requiring regular red blood cell (RBC) transfusions and chelation treatment.
View Article and Find Full Text PDFHBE homozygous haemoglobinpathy - Fortuitous finding.
J Oral Maxillofac Pathol
December 2022
Department of Oral and Maxillofacial Pathology, Chettinad Dental College and Research Institute, Chennai, Tamil Nadu, India.
A 24-year-old male patient presented with the principal complaint of deposits on his teeth and gingival pigmentation. After examination, he was diagnosed with chronic generalized gingivitis. He was further referred for pre-procedural routine blood investigations.
View Article and Find Full Text PDFDirect correction of haemoglobin E β-thalassaemia using base editors.
Nat Commun
April 2023
MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Haemoglobin E (HbE) β-thalassaemia causes approximately 50% of all severe thalassaemia worldwide; equating to around 30,000 births per year. HbE β-thalassaemia is due to a point mutation in codon 26 of the human HBB gene on one allele (GAG; glutamatic acid → AAG; lysine, E26K), and any mutation causing severe β-thalassaemia on the other. When inherited together in compound heterozygosity these mutations can cause a severe thalassaemic phenotype.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!